Imlifidase Prior to Kidney Transplant in Highly Sensitised Children
← catalyst calendarNCT05753930 · readout in 192 d
Sponsored by Hansa Biopharma AB (industry) · HNSA.ST — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
10estimated
Sites
6
Countries
Finland, France, Spain +2
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-06-02 | actual | When the study began enrolling |
| Primary completion | 2027-02-28 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2031-08-31 | estimated | The whole study's end, after follow-up |
| First posted | 2023-03-03 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-18 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Kidney Transplantation in Highly Sensitized Patients
Intervention
- Drug: Imlifidase — also filed as IdeS, HMED-IdeS
Primary outcome
what the primary-completion date above is the date OFProportion of patients with conversion of a positive crossmatch test to negative within 24 hours after start of imlifidase treatment
measured From start of imlifidase administration to 24 hours
Publications
- PMID 32463180 — cited as background
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · HNSA.ST's whole pipeline · Catalyst calendar · Every registered study · What changed